netFormulary NHS
Bedfordshire and Luton Joint Formulary
Bedford Hospital NHS Trust
Bedfordshire CCG
Luton & Dunstable University Hospital NHS Foundation Trust
Luton CCG
 Search
 Results

Looking for Adalimumab found 35 matches

Formulary items 8 matches
   
Formulary BNF Category
  Restricted Drug  Adalimumab  (Imraldi)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Restricted Drug  Adalimumab  (Humira)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Restricted Drug  Adalimumab 40mg  (Humira)
(Rheumatology)
Cytokine modulators - 10.01.03
  Restricted Drug  Adalimumab 40mg  (Humira )
(Ophthalmology)
Other anti-inflammatory preparations - 11.04.02
  Restricted Drug  Adalimumab 40mg  (Humira)
(Dermatology)
Drugs affecting the immune response - 13.05.03
  Restricted Drug  Adalimumab 40mg  (Imraldi)
(Rheumatology)
Cytokine modulators - 10.01.03
  Restricted Drug  Adalimumab 40mg  (Imraldi)
(Dermatology)
Drugs affecting the immune response - 13.05.03
  Restricted Drug  Adalimumab 40mg  (Imraldi )
(Ophthalmology)
Other anti-inflammatory preparations - 11.04.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section  NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.02)
link in drug section NICE TA146: Adalimumab for the treatment of adults with psoriasis (13.05.03)
link in drug section NICE TA146: Adalimumab for the treatment of adults with psoriasis (13.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in subsection NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (01.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.02)


 

netFormulary